Details for New Drug Application (NDA): 021462
NDA 021462 describes ALIMTA, which is a drug marketed by Lilly and is included in one NDA. It is available from one supplier. Additional details are available on the ALIMTA profile page.
The generic ingredient in ALIMTA is pemetrexed disodium. There is one drug master file entry for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the pemetrexed disodium profile page.
The generic ingredient in ALIMTA is pemetrexed disodium. There is one drug master file entry for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the pemetrexed disodium profile page.
Summary for 021462
| Tradename: | ALIMTA |
| Applicant: | Lilly |
| Ingredient: | pemetrexed disodium |
| Patents: | 0 |
Pharmacology for NDA: 021462
| Mechanism of Action | Folic Acid Metabolism Inhibitors |
Medical Subject Heading (MeSH) Categories for 021462
Suppliers and Packaging for NDA: 021462
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ALIMTA | pemetrexed disodium | POWDER;INTRAVENOUS | 021462 | NDA | Eli Lilly and Company | 0002-7623 | 0002-7623-01 | 1 VIAL in 1 CARTON (0002-7623-01) / 20 mL in 1 VIAL |
| ALIMTA | pemetrexed disodium | POWDER;INTRAVENOUS | 021462 | NDA | Eli Lilly and Company | 0002-7640 | 0002-7640-01 | 1 VIAL in 1 CARTON (0002-7640-01) / 4 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | EQ 500MG BASE/VIAL | ||||
| Approval Date: | Feb 4, 2004 | TE: | AP | RLD: | Yes | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INTRAVENOUS | Strength | EQ 100MG BASE/VIAL | ||||
| Approval Date: | Sep 7, 2007 | TE: | AP | RLD: | Yes | ||||
Complete Access Available with Subscription
